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List of abbreviations 
AE acetate EDTA 
APC antigen presenting cell 
ATC classification anatomical therapeutic chemical classification 
C. albicans Candida albicans 
cDNA complementary desoxiribonucleic acid 
CI cell index 
CKM complete keratinocyte medium 
control hyphae 
C. albicans hyphae three hours post infection in serum free CKM without 
PK E6/E7 VECL cells 
cph1Δ cph1 mutant 
dac1Δ dac1 mutant 
DEG differentially expressed gene 
EDTA ethylenediaminetetraacetic acid 
efg1Δ efg1 mutant 
ePCR emulsion polymerase chain reaction 
EtOH ethanol 
FDR false discovery rate 
GEO Gene Expression Omnibus 
GlcNAc N-acetylglucosamine 
HCl hydrogen chloride 
hgc1Δ hgc1 mutant 
hxk1Δ hxk1 mutant 
MHC major histocompatibility complex 
model hyphae 
C. albicans hyphae three hours post infection in serum free CKM infected 
with PK E6/E7 VECL cells 
mRNA messenger ribonucleic acid 
nag1Δ nag1 mutant 
NaOAc sodium acetate 
ngt1Δ ngt1 mutant 
nrg1Δ nrg1 mutant 
nt nucleotide 
PASI psoriasis area and severity index 
PCR polymerase chain reaction 
PDI protein-DNA interaction 
PPI protein-protein interaction 
QRT-PCR quantitative real-time polymerase chain reaction 
RIN RNA integrity number 
RNA-Seq ribonucleic acid sequencing 
RTCA real time cell analysis 
SD standard deviation 
SDS sodium dodecyl sulfate 
TBE tris borate EDTA 
TCR T cell receptor 
TE tris EDTA 
TF transcription factor 
Th1 T helper 1 cell 
Th17 T helper 17 cell 
VECL vaginal epithelial cell line 
VVC vulvovaginal candidiasis 
YPD 1% yeast extract, 2% peptone, 2% glucose/dextrose 
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1. Introduction 
1.1. The role of systems biology in the research of multifactorial diseases 
Most common diseases are caused by numerous internal and environmental factors. 
Multiple intracellular discrepancies in gene expression and in protein abundance can be found 
causing the phenotype of these diseases. Thus, the investigation of the system instead of one 
gene or protein have become necessary to understand disease mechanisms and find the most 
effective treatments [1]. I am going to demonstrate high-throughput gene expression studies for 
two multifactorial diseases: the infectious vulvovaginal candidiasis (VVC) and the non-
infectious psoriasis. In the first study, we constructed an in vitro model of VVC and carried out 
RNA-Seq analysis to identify virulence factors of the fungus. In the second one, we have done 
a meta-analysis of published microarray data about psoriasis, which was further processed in 
silico with a network-based approach. In both studies, we looked for potential proteins, which 
may have role in pathogenesis and could be modulated with drugs. We identified potential drug 
candidates as well for psoriasis. 
The physiologic and pathogenic role of the microbiome has become an important field 
of medical sciences in the recent years. Huge amount of large-scale data about microorganisms 
in the normal human flora is available in multiple databases. Genetic, genomic, metagenomic, 
epigenomic, transcriptomic, proteomic, metabolomic and evolutionary analysis have become 
main-stream methods in biomedical research [2]. High throughput sequencing made it possible 
to analyze genomes, epigenomes, transcriptomes and the constitution of microbes during 
infection. As a result, more effective identification of virulence factors and, thus, potential drug 
targets have become possible [3]. 
Psoriasis is one of the most studied skin diseases. More than 39000 hits are available 
currently in PubMed for the keyword „psoriasis” and the number is increasing. “Omics” data 
gives the opportunity to examine the disease with systems biology approach. With this, it has 
become possible to reveal new treatment options and to understand the disease better [4]. The 
way we handle huge datasets is crucial to get reliable results. The proper use of bioinformatics 
tools for filtering, normalization and statistical processing is essential to avoid false inferences. 
In silico model construction is possible only after these steps [5]. 
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1.2. Vulvovaginal candidiasis 
1.2.1. Epidemiology 
Infections related to candida species are common. The majority of infections are caused 
by C. albicans, although the prevalence of other, non-albicans Candida species is 
increasing [6,7]. Candidiasis affects the mucosal surfaces and the skin of healthy people, but 
life-threatening invasive candidiasis can be developed in severely immunocompromised 
individuals [7]. C. albicans is the member of the normal vaginal flora in 10-20 % of women 
and can be found in the normal oral flora of individuals ranging from 7.7 to 70% depending on 
geographical factors [8]. Most common form of C. albicans infections is VVC. 75 % of women 
are affected at least once in their lives, and around 5 - 10% of them have recurrent infections [6]. 
Prevalence of the disease is affected by sexual activity, age, diabetes mellitus, the use of 
antibiotics, pregnancy etc. [9] 
1.2.2. Clinical characteristics 
VVC frequently affects otherwise healthy women. However, the disease is more 
common in patients with diabetes mellitus, after the use of broad-spectrum antibiotics and 
during pregnancy [9]. Interestingly, the prevalence is not increased in diseases, which are 
characterized with decreased adaptive immune defense [6]. Most important signs of VVC are 
the erythema, the itch of the vulva, the erythema of the vagina, and a thick, white discharge 
[10]. 
1.2.3. Pathogenesis and immune defense 
C. albicans is a dimorphic fungus exhibiting non-pathogenic yeast morphology as a 
member of the normal human flora as well as pathogenic hyphal morphology. C. albicans is 
adapted to its mammalian host in several ways and hyphal growth can be induced by several 
factors. Everything that makes the environment unfavorable for the fungus, induces the hyphal 
transcriptional program [11]. Filamentous form causes cell damage by penetration. Induced 
phagocytosis of the yeast is also prevalent. Several invasin molecules mediate the uptake of the 
fungus by host cells [12]. Filamentous growth is then initiated in the phagosome and hyphae 
cause cell lysis [13]. 
Morphological switch itself is required for pathogenesis as virulence is decreased in 
mutants constantly staying in yeast (efg1Δ/cph1Δ, hgc1Δ) or hyphal (nrg1Δ) morphologies. A 
complicated signal transduction network regulates this switch [11]. The dimorphism has an 
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effect on the antigenicity, thus, immune evasion of C. albicans [12]. An important initial step 
during pathogenesis is adhesion. A large set of adhesins and a complex regulatory machinery 
have already been identified [14]. After adhesion and hyphal induction, penetration is facilitated 
by a set of secreted aspartic proteases [15]. Several fitness traits can also be considered as 
virulence factors, such as the stress response by heat shock proteins, auto-induction of 
filamentation, metabolic flexibility and the uptake of metals and other compounds [12]. 
Differentiation between the two forms is present on the level of innate recognition. 
Pattern recognition receptors recognize glycoproteins on the surface of the fungus in a non-
specific way. The cell wall constitution of yeast is different from hyphae [16]. Cell wall 
remodeling starts at the beginning of filamentation. Filamentous form induces immune-
response, while the commensal form is less immunogenic [16]. 
The particular role of adaptive immunity against C. albicans is less well described. 
Several studies reported the presence of C. albicans-specific antibodies in the circulation 
[17,18]. Induction of the cellular adaptive immune response, which has also been described, 
contributes more significantly to defense mechanisms against candidal infection, than humoral 
factors. Cellular adaptive immune response against C. albicans (and numerous other fungal 
pathogens) involves antigen presenting cells (APCs), such as macrophages and dendritic cells, 
which present short peptides (epitopes) bound to major histocompatibility complex (MHC) II 
molecules on the cell surface. C. albicans-specific epitopes are recognized by T-cell receptors 
(TCRs) on the surface of T helper (Th) cells [19]. Taking place at the so-called immunological 
synapse, immunological recognition involves APCs, MHC II molecules, epitopes, TCRs and 
Th cells [20]. Epitope binding to its specific TCR activates Th1 and Th17 cells, which then 
recruit neutrophil granulocytes and monocytes to the place of infection by expressing interferon 
gamma or IL17 [19,21]. Noteworthy, that the site of infection significantly affect immune 
response. While adaptive immune system has a significant role during the course of the disease 
on the mucosal surfaces of the gastrointestinal tract, only the role of innate immunity is 
supposed in case of VVC [6]. 
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1.3. Psoriasis 
1.3.1. Epidemiology and clinical characteristics 
Psoriasis is a multifactorial inflammatory skin disease. A recent systematic review 
reported a prevalence from 0% (Taiwan) to 2.1% (Italy) in children and from 0.91% (United 
States) to 8.5% (Norway) in adults [22]. Psoriasis is more common in the Caucasian race 
compared to African Americans in the USA [23]. The disease is usually chronic and recurrent. 
Patients have hyperkeratotic, scaly patches on their skin. Predilection sites are the elbows, knees 
and the sacral area, but it can also affect the scalp, nails and the whole skin surface [24]. 
Sometimes very severe forms can be developed affecting almost 100% of the skin. This life-
threatening condition is called erythroderma. Psoriasis is associated with a rheumatic disease 
called psoriatic arthritis, which develops in 5 - 30% of psoriasis patients [24]. 
1.3.2. Pathophysiology 
Genetic predisposition and environmental factors are both important in disease etiology. 
Several genome-wide association studies have been carried out and until now 36 susceptibility 
loci have been identified [25]. Environmental triggers are also reported such as drugs, smoking, 
mental stress, skin injury, Streptococcal infection, hormonal changes etc [26]. Psoriasis is an 
immune-mediated disease. Important immune cells and cytokines have been identified in 
disease pathogenesis such as IL6, IL17A, TNF etc [27]. Autoimmune basis for chronic 
inflammation is supposed, although no consistent antigen has been found. Patients with 
psoriasis have higher risk for metabolic syndrome, and risk increases with disease severity. 
Both diseases have immunological basis with common cytokines and genetic risk loci like 
CDKAL1 [28]. Keratinocyte hyperproliferation is present in lesional phenotype and is 
responsible for scale formation. Keratinocyte differentiation markers like keratin 1 and keratin 
10 are downregulated and parakeratosis (keratinocytes with nuclei in the stratum granulosum) 
is present [26]. 
1.3.3. Treatment 
Numerous treatment options are available, but no “golden standard” have been 
developed. Treatment recommendations vary depending on disease severity, co-morbidities and 
treatment history [24]. Treatment options can be classified into local, UV-light and systemic 
groups. Most common local therapies are steroids, vitamin D3 analogues, dithranol, retinoids 
and calcineurin inhibitors. Mainstream systemic therapeutic options are methotrexate, 
calcineurin inhibitors and biological therapy [24]. 
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A general consideration is that different patients respond to treatment options with 
different extent. In some cases, treatment worsens the disease instead of improving it. There are 
also treatment-resistant cases [29]. All of these facts suggest, that psoriasis is much more 
complex than how we are now understanding it and systematic analysis of the diseases is 
required to acquire further aspects of pathogenesis. 
1.4. High throughput screening of gene expression 
1.4.1. Microarray 
Stationary changes in gene expression are responsible for fixing phenotypes such as the 
lesional skin area in psoriasis. DNA microarray is a widely used method for large-scale 
screening of gene expression. Fixed DNA probes binding different DNA sequences are fixed 
to a solid surface. RNA is reverse transcribed to DNA and then complementary DNA (cDNA) 
is fluorescently labelled. cDNA is then hybridized to DNA on the microarray chip, and the non-
specific sequences are washed down. Laser-based detection of the fluorescence is possible, 
which is proportional with the abundance of sequence specific cDNA, thus with the abundance 
of mRNA [30]. Large scale screening of splicing, single nucleotide polymorphisms (SNP), 
transcription factor binding sites, fusion genes etc. has become possible with the improvement 
of microarray technology. After registering fluorescence, in silico normalization and filtering 
of data is crucial [5]. Microarray is relatively cheap and broad spectrum of bioinformatical 
methods and libraries are present for the analysis of microarray data [5]. One disadvantage 
opposed to high-throughput sequencing is, that microarray cannot reveal new transcripts, only 
predestinated sequences can be detected [31]. 
Several microarray studies have been carried out to characterize gene expression in 
healthy and psoriatic skin samples (Table 1). Microarray meta-analysis gives the opportunity 
to evade biological, regional, and study design-caused variation between studies [32]. 
1.4.2. Next generation sequencing 
High throughput sequencing technologies emerged in the 1990s [33]. Researchers are 
able to get sequences of whole genomes and transcriptomes, but these technologies can also be 
used for different other purposes like characterizing DNA-protein interactions (ChIP-
sequencing) and the epigenome. The cost of these assays were high, but the price is constantly 
getting lower making their use possible in basic research [34]. Compared to the classical “chain 
termination” based Sanger sequencing, these methods are much faster, have higher sequencing 
capacity and lower cost. The most popular ones are ligation based sequencing (SOLiD), 
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synthesis-based sequencing (Illumina), pyrosequencing (454) and ion torrent sequencing 
methods [34]. 
We used SOLiD sequencing for our VVC study. A large set of possible polynucleotide 
sequences with fixed length is labelled and ligated to the query DNA sequence. This ligation 
results in signal, which is detected by the sequencer. It is important to amplify the cDNA by 
emulsion PCR before ligation [35]. 
Beside the already mentioned advantages of next generation sequencing, another one is 
its ability to identify novel transcripts. Although the cost of these methods is getting lower, it 
can be still very expensive to use biological replicates. If this is the case, validation of results 
is essential. 
1.5. Network analysis 
1.5.1. Introduction 
Network analysis is a novel and highly developing area of systems biology. Considering 
gene expression data, it is possible to explain alterations in intracellular processes with the 
analysis of protein-protein and protein-DNA (or gene regulatory) interaction networks. These 
networks consist of proteins and/or regulated genes as nodes and undirected or directed edges 
between them [36]. 
1.5.2. Scale-free networks, centralities and motifs 
Centralities, like degree or stress, are suitable for ranking nodes. Total edge number 
belonging to one node equals its degree in undirected networks. Nodes have in- and out-degrees 
based on edge directions in directed networks [36]. Degree values follow a scale-free power 
law distribution in biological networks. This fact indicates that highly connected vertices have 
a large chance of occurring. Nodes with highest degree are called hubs and are essential in 
network stability [37]. Stress centrality indicates the number of shortest paths (from all shortest 
paths between any two nodes in the network) passing through the given node and, thus, the 
capability of a protein to hold together communicating nodes [38]. Interconnected nodes make 
up network motifs. Several motifs, such as the feed-forward or bifan motif are significantly 
enriched in biological networks compared to random networks. These elements have important 
role in network dynamics [39]. 
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1.5.3. Network analysis in biomedical research and drug development 
It is important to investigate intracellular proteins as members of an intracellular 
network. Since the description of scale-free networks in the late 90s, rapid development can be 
seen in the field of network-based analysis of large-scale datasets [40]. Multiple in silico 
methods and software are developed and are widely used. We can consider biological pathways 
as networks and analyze processes instead of individual proteins, genes or metabolites. A large 
set of pathway databases is available online like KEGG, Reactome, Ingenuity etc. [41] We can 
also construct custom networks based on protein-protein and protein-DNA interaction 
databases, like STRING or CisRED [42,43]. 
Network analysis is also prevailing in drug discovery. Identification of new drug targets 
is essential. For this, first, the integration of all information about the model biological system 
is needed. The most plausible way is to create networks. Network based approaches can help 
us to predict drug side-effects, drug-drug interactions and can be used in numerous other fields 
of drug discovery [4].  
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2. Aims I 
Despite recent advances are made in our understanding of disease pathogenesis caused 
by C. albicans, little is known about the mechanisms that underlie hyphal transition in response 
to contact with human vaginal epithelial cells. We managed to construct an in vitro model of 
VVC. We hypothesized that the characteristics of hyphae growing in the presence of human 
cells is markedly different from control hyphae, which grow without human cells. We also 
supposed, that genes, that are solely differentially expressed in the presence of human cells can 
potentially be virulence factors. 
3. Aims II 
Our goal was to construct reliable but yet detailed protein-protein, protein-DNA, merged 
(containing both protein-protein and protein-DNA interactions) and chemical-protein 
interaction networks consisting of differentially expressed genes (DEG) between lesional and 
non-lesional skin samples of psoriatic patients and/or the coded proteins. We hypothesized, that 
it could be possible to find novel elements in psoriasis pathogenesis and potential drug 
candidates with the detailed analysis of these networks. 
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4. Methods I 
4.1. Strains, growth conditions and cell culturing 
C. albicans clinical isolate SC5314 was grown on YPD medium at 30°C, cultured under 
standard conditions until logarithmic phase, and then counted with a haemocytometer. The 
immortalized human vaginal epithelial cell line (VECL) PK E6/E7 [44] was cultured in serum-
free complete keratinocyte medium (CKM) supplemented with 5 ng/mL recombinant epidermal 
growth factor, 50 μg/mL bovine pituitary extract, L-glutamine, and antibiotic/antimycotic 
solution (all from Life Technologies) in a CO2 thermostat at 37°C [45]. Cells at 60–70% 
confluency were used in subsequent experiments. A total of 105 PK E6/E7 VECL cells were 
seeded in 6-well plates and incubated for 24 hours in serum-free CKM. At 24 hours prior to 
infection with C. albicans, the medium was changed to serum-free CKM (pH 8.0) without 
antibiotic/antimycotic solution. Fungal cells were collected in log phase, washed three times 
with CKM, and then resuspended in complete CKM without antibiotic/antimycotic solution to 
eliminate farnesol. In order to induce hyphal growth, plates were incubated in a CO2 thermostat 
at 37°C (control hyphae). Fungal cells, treated the same way, were added to wells with a 
multiplicity of infection (MOI) of 3:1 to infect PK E6/E7 VECL cells. Yeast control cells were 
harvested at 0 hour time point. Plates were incubated for 3 hours in a humidified atmosphere 
containing 5% CO2 at 37°C; fungal cells rapidly switch to filamentous growth under such 
circumstances. Ten randomly chosen fields of view were used to count C. albicans hyphae 
penetrating into vaginal epithelial cells. 
4.2. Viability test 
The effect of C. albicans infection on the viability of PK E6/E7 VECL cells was 
measured by Real-Time Cell Analysis (RTCA; ACEA Biosciences), as described previously 
[46-48]. Briefly, 104 PK E6/E7 cells per well were seeded in 96-well E-plates (ACEA 
Biosciences) in which the bottom of the wells were covered with micro electrodes. Epithelial 
cells were allowed to attach to the bottom of the wells and grow for 3 days. Cells were then 
treated with 2 × 103, 5 × 103, 1 × 104, and 2 × 104 C. albicans hxk1Δ or DIC185 cells/well. 
Triton-X (Sigma) treatment was used as a positive control to kill the vaginal epithelial cells. 
Real-time measurements of impedance were done with the xCELLigence System RTCA HT 
Instrument (ACEA Biosciences); the impedance was monitored every 10 minutes. The cell 
index at each time point was defined as (𝑅𝑛 − 𝑅𝑏)/15, where 𝑅𝑛  is the cell-electrode 
impedance of the well when it contains cells and 𝑅𝑏 is the background impedance of the well 
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with the medium alone. The cell index (CI) was normalized to the latest time point before the 
treatment of each group (CIn/CI before treatment) or presented as percent of non-treated control 
group [(CIn/CI average of control group) × 100]. CI values reflect cell number, adherence, cell 
growth, and health. Data is presented as means ± standard deviation (SD). Statistical 
significance between treatment groups was determined using one-way and two-way ANOVA 
following pairwise T tests with Bonferroni correction (GraphPad Prism 5.0; GraphPad 
Software). Experiments were repeated three times and the number of biological replicates 
varied between 3 and 6. 
4.3. C. albicans adherence assay 
PK E6/E7 VECL cells were grown in 6-well plates until confluency was reached 
(>90%). The hxk1Δ mutant and the parental strain (DIC185) [49] were grown on YPD plates 
for 24 hours. A total of 105 cells re-suspended in CKM were used to infect vaginal epithelial 
cells for 90 minutes. Supernatant was then aspirated and the wells were washed two times with 
1× PBS. The monolayers with attached C. albicans were fixed by 3.7% (v/v) paraformaldehyde 
in PBS. Quantitation of C. albicans adherence was performed by light microscopy at a 25x 
magnification. Ten randomly chosen fields of view covered with epithelial cells were counted. 
Significance was calculated with a two-sample T test and a p value of less than 0.05 was 
considered to be significant. Experiments were performed with three biological replicates. 
4.4. Total RNA isolation and high throughput sequencing 
Cells were harvested and re-suspended in 400 μL AE buffer (50 mM NaOAc, 10 mM 
EDTA); 40 μL 10% SDS and 440 μL of phenol were added and the samples were vortexed. The 
mix was incubated at 65°C for 10 minutes and frozen in liquid nitrogen. After thawing, the 
samples were centrifuged with 10000 G for 2 minutes; the upper phase was extracted with 
phenol-chloroform and precipitated with 1/10th volume of 3 M NaOAc and 2.5 × volume of 
96% ice cold EtOH. Finally, the samples were centrifuged (10000 G, 15 min), the supernatant 
was discarded, and the pellet was washed with 70% EtOH and resuspended in TE buffer 
(10 mM Tris-HCl, 1 mM EDTA, pH 7.5). RNA quality and quantity measurements were 
performed on Bioanalyzer (Agilent Technologies) and Qubit (Life Technologies). Whole 
transcriptome sequencing was performed as described previously [50]. Briefly, total RNA 
samples from three biological replicates were pooled in equimolar concentrations and processed 
using the SOLiD total RNA-Seq Kit (Life Technologies), according to the manufacturer’s 
instructions. For this, 5 μg of pooled RNA was DNaseI treated and fragmented using RNaseIII; 
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the eukaryotic ribosomal RNA was depleted prior to fragmentation using RiboMinus Eukaryote 
Kit for RNA-Seq and RiboMinus Concentration Module (Life Technologies). Next, the 50–
200 nt RNA fraction was size-selected, sequencing adaptors were ligated, and the templates 
were reverse-transcribed using ArrayScript reverse transcriptase. The cDNA library was 
purified with Qiagen MinElute PCR Purification Kit (Qiagen) and size-selected on a 6% TBE-
Urea denaturing polyacrylamide gel. The 150–250 nt cDNA fraction was amplified using 
AmpliTaq polymerase and purified by AmPureXP Beads (Agencourt). The concentration of 
each library was determined using the SOLID Library TaqMan Quantitation Kit (Life 
Technologies). Each library was clonally amplified on SOLiD P1 DNA Beads by emulsion 
PCR (ePCR). Emulsions were broken with butanol and ePCR beads were enriched for template-
positive beads by hybridization with magnetic enrichment beads. Template-enriched beads 
were extended at the 3′ end in the presence of terminal transferase and 3′ bead linker. Beads 
with the clonally amplified DNA were deposited onto SOLiD flowchip and sequenced on 
SOLiD V4 instrument using the 50 + 35-base paired-end sequencing chemistry. 
4.5. Bioinformatical and statistical analysis 
Bioinformatical analysis of the whole transcriptome sequencing was performed in color 
space using Genomics Workbench (CLC Bio). Raw sequencing data was trimmed by removal 
of low quality, short sequences so that only 50 + 35 nucleotide long sequences were used in 
further analysis. Sequences were mapped in a strand specific way onto the C. albicans SC5314 
assembly 19 reference genome [51] using default parameters except for the following: 
minimum length 50% and minimum similarity 80% with the unspecific match limit set to 10. 
Normalized gene expression was calculated using the “scaling” normalization method [52]. The 
three sequenced libraries were deposited in NCBI’s Gene Expression Omnibus (GEO) Archive 
at http://www.ncbi.nlm.nih.gov/geo under accession GSE54694. Differentially expressed genes 
from the RNA-Seq output were determined using the R package DEGSeq. The software 
calculates significance with an MA-plot method for RNA-Seq data without biological 
replicates. Gene expression was considered significantly different between two conditions if 
the false discovery rate (FDR) corrected probability (p) value was less than 0.05 [53] and the 
absolute fold change value was more than 2 [54]. 
4.6. Quantitative reverse transcriptase polymerase chain reaction (QRT-PCR) 
cDNA was synthesized from at least 100 ng of high quality (RIN > 8.5) total RNA by 
using the High Capacity RNA-to-cDNA Kit (Life Technologies) according to the 
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manufacturer’s instructions. SybrGreen technology-based real-time quantitative PCR was used 
to quantify the relative abundance of the selected mRNAs. As controls, we used reaction 
mixtures without cDNA. Relative expression of the given gene in the yeast-like form was set 
to 1 and the expression in control hyphae and hyphae developed in the presence of PK E6/E7 
vaginal epithelial cells was calculated by comparing the values to the yeast form. Two technical 
and three biological replicates were used. The ratio of each mRNA relative to the 18S rRNA 
was calculated using the 2−𝛥𝛥𝐶𝑇 method; all the data are presented as mean ± SD. Differential 
expression was assessed with one-way ANOVA followed by pairwise t-test and Bonferroni p 
value correction.  
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5. Methods II 
5.1. Microarray meta-analysis 
Six microarray studies examining lesional and non-lesional skin biopsy samples of 
psoriatic patients were found in GEO (Table 1). “Minimum Information About a Microarray 
Experiment” (MIAME) was available for each study. Only non-lesional and lesional samples 
from affected individuals were used for analysis, samples of healthy individuals were excluded. 
Raw .CEL files were downloaded and quality of each sample was assessed with the R package 
arrayQualityMetrics [55]. This package defines sample quality with 5 different methods and 
generates plots for outlier detection. A sample was excluded if it was obviously an outlier in at 
least 1 measure or had borderline values in at least 2 measures. Raw data normalization of 
remaining samples was carried out with the R package Easy Microarray data Analysis 
(EMA).[5] GCRMA normalization method was used and probe sets with expression level 
below 3.5 were discarded. Probe set with the highest interquartile range (IQR) was chosen for 
common HUGO Gene Nomenclature Committee (HGNC) gene identifiers. Original findings 
were confirmed with published statistics and EMA was used for this after GCRMA 
normalization. More DEGs were found in some cases, which might be caused by the pre-
filtering process with arrayQualityMetrics. The R package MetaQC was used for filtering out 
low quality studies [56]. The fifty most prevalent gene sets were chosen with the software Gene 
Set Enrichment Analysis (GSEA) and used for external quality control (EQC) score calculation 
[57]. GSEA was carried out for each study with the following settings: 1000 permutations; 
minimum set size was 5 and the gene set database was c2.all.4.0.symbols. The resultant study-
level p values of a gene set were combined with Fisher’s combined probability test. The fifty 
gene sets with the lowest meta-analysis p value were chosen as input for EQC score calculation. 
C2.all.4.0.symbols gene set database was chosen as input for consistency quality control 
(CQCp) value calculation. GSEA input expression matrices contained gene IDs that were 
present in all studies after EMA filtering. MetaDE package was used to determine DEGs in 
lesional samples compared to non-lesional ones [58]. DEG p values for individual studies was 
calculated by two sample T test with unequal variances. Fisher’s combined probability test was 
chosen for meta-analysis statistical method [59]. Fold change of gene expression was given by 
the ratio of gene expression geometrical means in lesional and non-lesional samples [60]. Genes 
with FDR less than 0.001 and with fold change higher than 1.5 or less than -1.5 were accepted 
as DEGs. 
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5.2. Construction of protein-protein, protein-DNA and chemical-protein interaction 
networks 
STRING database 9.0 was used as resource for protein-protein interactions (PPI) [42]. 
Both directed and undirected networks were created by selecting all interactions between DEG 
– coded proteins in raw STRING data. Interactions with a confidence score higher, than 900 
(“highest confidence” group) were used in case of undirected network construction and 800 
(containing a part of “high confidence” and all “highest confidence” interactions) in case of 
directed network construction. Only directed interactions with “activation”, “inhibition” or 
“ptmod” action properties were used. Chemical-protein interactions between potential drugs, 
intra- and extracellular compounds and DEG-coded proteins were collected from STITCH 
database 3.1.[61] Confidence score calculation is the same in this database as in STRING thus 
interactions with the described confidence score cutoff values were selected for network 
construction. Protein-DNA interaction (PDI) network consisting of DEGs and DEG-coded 
transcription factors (TF) was created using cis-Regulatory Element Database (CisRED) [43]. 
Regulatory element motifs with p 0.001  were collected from DEG promoter regions. Motifs 
were coupled with TFs or TF complexes using TRANSFAC and JASPAR databases [62,63]. 
Motifs without respective TFs were excluded. Merged DEG-derived network containing PPI 
and PDI interactions and a network containing only DEG-coded TFs were also generated. 
Complete PPI, PDI, merged, TF-TF and chemical-protein interaction networks were created for 
controls using all available interactions in databases with the same statistical threshold as in 
DEG-derived network construction. 
5.3. General network analysis, identification of central nodes and motif detection 
General network analysis and node centrality value calculation were carried out with 
NetworkAnalyzer Cytoscape plugin [64]. Isolated nodes and node groups (without connection 
with the main PPI network) were deleted from graph in order to evade false results. Curve 
fitting on node degree and stress value distributions was done with MATLAB Curve Fitting 
Tool (MATLAB R2012b, The Mathworks Inc., Natick, MA). Curve of power law distribution 
was assessed with Trust-Region algorithm. Goodness of fit was assessed by R-square and 
corrected R-square values. Power law distribution of these node centralities was proven, as R-
squared values were ranged from 0.87 to 1.0. As power law distribution is asymmetric with a 
long tail, it cannot be described with classical statistics used for Gaussian distribution. A 
variable with a power-law distribution has a probability 𝑃(𝑘) of taking a value k  following the 
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function 𝑃(𝑘)~𝐶𝑘−𝛾, where 𝐶 is constant. First moment (mean value) of a power-law 
distributed quantity equals: 
〈𝑘〉 =  
𝛾 − 1
𝛾 − 2
𝑘𝑚𝑖𝑛; (𝛾 > 2) 
Second moment (variance) of a power-law distributed quantity equals: 
〈𝑘2〉 =
𝛾 − 1
𝛾 − 3
𝑘𝑚𝑖𝑛
2 ; (𝛾 > 3) 
The sum of first and second moment (mean value and variance) was used as cutoff for 
centralities with distribution exponent of 3  . Expression of variance becomes infinite, if 
3  , thus only first moment (mean value) was used as cutoff for centralities with distribution 
exponent 2 3    [65]. Expression of mean value becomes infinite, if 2  . In this case 
weighted mean was used to assess cutoff with the following formula: 
〈𝑘〉 =
∑ 𝑘𝑖
1
𝐶𝑘𝑖
−𝛾
𝑛
𝑖=0
∑
1
𝐶𝑘𝑖
−𝛾
𝑛
𝑖=0
 
  As bidirectional connections are available in undirected PPI network, stress centrality is 
independent from edge directions, thus, both degree and stress had to be above cutoff for central 
protein selection. As directed networks contain unidirectional interactions, low stress values 
(i. e. low number of shortest paths cross through the node) can be caused by the dominance of 
incoming (in-degree) or outgoing (out-degree) interactions. Important nodes with high in-
degree or out-degree can still have low stress centrality thus either out-degree or in-degree or 
stress had to be above cutoff in directed PPI network. As TFs have mainly outgoing interactions, 
out-degree was used for TF prioritization. Similarly to PPI networks, degree and stress had to 
be above cutoff in undirected chemical - protein interaction network. Drugs with more targets 
in DEG-derived PPI-networks may have bigger disease modifying effect, thus out-degree had 
to be above cutoff in directed chemical – protein interaction network for drug prioritization. 
NetMODE software was used for network motif statistical analysis. Frequency of 3 or 
4 node motifs in DEG-derived and complete control networks were compared with 1000 
random graphs. Local constant switching mode was used for edge switching method during 
random network generation. NetMODE 𝑝 value indicates the number of random networks in 
which a motif occurred more often than in the input network, divided by total number of random 
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networks. 𝑝 < 0.05 was used as cutoff [66]. Respective sub-networks of enriched motifs were 
identified with NetMatch Cytoscape plugin [67].  
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6. Results I 
6.1. Vaginal epithelial cell - C. albicans co-culture as a model of vulvovaginal 
infection 
Infection of epithelial cells by C. albicans requires adhesion of yeast form cells to the 
surface of epithelium. We used the immortalized PK E6/E7 VECL [44] cultured in serum-free 
CKM, containing 1.0 g/L (0.1 v/w%, or 5.6 mM) glucose, and infected them with C. albicans 
SC5314 yeast form cells (Figure 1a). Since we aimed to monitor the primary effect of human 
cells on hyphae formation, we sampled the cells at 3 hours post infection. Notably, conditions 
changed drastically in our culturing environment. CO2 concentration and temperature 
increased, and neutral pH changed to alkaline, all of which are known to strongly induce the 
morphological transition of C. albicans [68]. Thus, C. albicans cells adhered to the surface of 
PK E6/E7 VECL and developed hyphae and approximately 5% of hyphae penetrated into 
epithelial cells (Figures 1c and 1d). We call this sample “model hyphae” for simplification. 
C. albicans cells were cultured in serum-free CKM without human cells for 3 hours as 
control. Microscopic examination showed that at this time point C. albicans cells are adhering 
to the surface of the culture chamber and develop hyphae even in the absence of serum (Figure 
1b). We call this sample “control hyphae” for simplification. Importantly, control hyphae and 
model hyphae could not be distinguished in terms of the timing of the morphological switch, 
rate of hyphae development, or length of hyphae (Figures 1b and 1c). 
6.2. Primary analysis of transcriptome data 
To study the early and specific molecular events occurring upon hyphae formation in 
the absence or presence of vaginal epithelial cells, global transcriptional changes of C. albicans 
cells were monitored using RNA-Seq. To do this, transcriptomes of yeast form C. albicans, 
control hyphae and model hyphae were sequenced on SOLiD System. Reads were aligned to 
the C. albicans SC5314 genome (assembly 19) and normalized gene expression values were 
calculated as described in materials and methods. Identification of DEGs between different 
forms of C. albicans was carried out with the R library DEGSeq. Genes with 2-fold absolute 
difference of gene expression and a FDR less than 0.05 were considered to be DEGs. 
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Figure 1 Microscopic analysis of C. albicans hyphal growth in vitro. Yeast form of C. albicans 
(a); C. albicans develops hyphae in CKM (b) and in the presence of PK E6/E7 vaginal epithelial 
cells (c). C. albicans hyphae penetrate into PK E6/E7 VECL cells (d, penetration sites are 
marked with red asterisk). 
Pairwise comparison resulted in 1283 DEGs between control hyphae and yeast. 
Surprisingly, almost twice as much, 2537 DEGs were found between model hyphae and yeast. 
We identified 1574 DEGs between the two hyphal forms. RNA-Seq data allowed us to identify 
384 DEGs with higher expression in both hyphae compared to yeast and no difference between 
the two hyphal forms. These genes might be considered as effector genes of hyphae formation 
as a response of culturing C. albicans in serum-free CKM. We found 376 DEGs upregulated in 
both hyphal forms compared to yeast and differentially expressed between control and model 
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hyphae. 1205 DEGs were exclusively found between model hyphae and yeast. These genes 
may play an important role in the virulence of C. albicans after contact with vaginal epithelial 
cells. 
6.3. Validation of RNA-Seq data by quantitative real-time PCR (QRT-PCR) 
QRT-PCR analysis were performed to validate the expression pattern of 22 genes 
(Figure 2). This gene set includes representatives of all the identified expression patterns (see 
above). The QRT-PCR analysis showed, that 15 genes (among others, CHS8, HOG1, and 
CDC53) were indeed significantly upregulated in model hyphae, but not in control hyphae. 
ARX1, MUP1, and GDA1 were upregulated in both hyphal forms, but no significant difference 
was found between the two hyphae. GCN4, EAP1, and TES2 were upregulated in both hyphae 
and there was significantly higher expression in model hyphae compared to control hyphae. 
Finally, expression of FOX2 was significantly downregulated in both model and control 
hyphae. The results of QRT-PCR analysis are in complete agreement with the RNA-Seq 
expression data (Figure 2). 
 
Figure 2 QRT-PCR validation of RNA-Seq results. The relative gene expression of selected 
genes shows altered expression upon hyphae development as compared to yeast-like growth. 
Black and open bars represent control and model hyphae, respectively. Data are representative 
of 3 or more independent experiments and are presented as mean ± SD. *𝑝 < 0.05. 
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6.4. Functional analysis of RNA-Seq data 
6.4.1. Analysis of signal transduction pathways involved in hyphal morphogenesis 
Our culturing conditions induced strong hyphal morphogenesis of C. albicans with or 
without PK E6/E7 VECL (Figure 1). We sought to determine if different signal transduction 
pathways leading to hyphal morphogenesis are responding to these conditions at the level of 
transcription. We found that the DCK1-RAC1 pathway, known to be required for filamentous 
growth in a matrix embedded microenvironment, is upregulated in control hyphae and further 
upregulated in model hyphae (Figure 3). Moreover, expression of MEP2 transducing low 
nitrogen signal towards RAS1 was also enhanced during hyphal growth (Figure 3). Neither the 
expression of the RAS1, which is known as a signal integrator, nor the expressions of CDC24 
or STE11 altered significantly. However, a significantly elevated expression was detected for 
CDC42, CST20, CEK1, and CPH1 in both hyphal forms (Figure 3), while HST7 expression 
increased only in model hyphae. The adenylyl cyclase (CYR1) pathway in C. albicans also 
functions as a signal integrator for different environmental conditions and is regulated directly 
by farnesol, CO2, glucose and methionine concentration, RAS1, and serum [11] (Figure 3). 
Expression of almost all components in the CYR1 pathway, such as GPA2, PDE2, TPK1, 
EFG1, and FLO8, was upregulated in both hyphal forms. Of note, we identified significant 
induction of EFG1 in both hyphae. EFG1 encodes a transcriptional activator and have a major 
role in the induction of the hypha-specific genes (Figure 3). FLO8 expression was upregulated 
in both hyphae, but less, than 2-fold in control.  
We also monitored the expression of the major repressors of hypha-specific genes. 
Slight, but significant increases in expression were observed for RBF1, TUP1 only in model 
hyphae. Interestingly, we found a moderate increase in the expression of RFG1 in control 
hyphae, but a robust upregulation was found in model hyphae. NRG1 was slightly upregulated 
in both hyphae. NRG1 and RFG1 are known to repress transcription of hyphae specific genes, 
along with TUP1 in response to serum and temperature [69]. Our results suggest that the ratio 
of transcriptional activators and repressors is crucial in the regulation of the hyphae specific 
genes, as upregulation of both activators and repressors could be seen (Figure 3). 
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Figure 3 Comparison of gene expression of signal transduction pathways and their components 
in vitro. Figure was redrawn from Sudbery [11]; genes are shown with gene names. Numbers 
show fold change of expression between control hyphae and yeast (C), and model hyphae and 
yeast (M). Non-significant changes (DEGSeq) in gene expression are marked by black 
characters; upregulation is marked by red characters and downregulation is marked by blue 
characters. 
N-acetyl-glucosamine (GlcNAc) is known to induce hyphal morphogenesis [70] and 
white opaque switching [71,72] in C. albicans. Interestingly, we found that the NGT1 gene 
representing the transporter gene in the GlcNAc transporter was solely significantly upregulated 
in model hyphae, indicating the specificity of this response to epithelial cells (Figure 3). 
We have identified a parallel upregulation of several hyphal induction pathways at the 
level of transcription both in the control hyphae and in hyphae induced by PK E6/E7. Some 
environmental factors with role in induction, such as glucose concentration and pH, were 
measured in order to register differentially changing environmental factors in the two hyphae, 
which could cause bias in the comparison of the two hyphal forms. We found, that pH reduced 
from 8.0 to 7.6 ± 0.04 in control hyphae and to 7.6 ± 0.02 in model hyphae. Glucose 
concentration was also reduced from 5.2 mM to 4.58 mM and 4.6 mM in control and model 
hyphae, respectively. These data show, that both pH and glucose concentration changed in a 
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similar way and extent in our in vitro system. These values are, however, still in the range, 
where yeast to hyphae transition of C. albicans is strongly induced [73,74]. 
6.4.2. Expression analysis of genes involved in GlcNAc metabolism 
As GlcNAc induces hyphal morphogenesis in C. albicans [75], we sought to monitor 
the expression of GlcNAc catabolic genes in our in vitro model. Since the RNA-Seq experiment 
did not provide sufficient number of unique reads for statistical analysis of this group (data not 
shown), the expression of several GlcNAc catabolic genes was tested by QRT-PCR. For this, 
the following conditions were used: control hyphae, model hyphae, and control hyphae 
supplemented with 10 mM of GlcNAc. Expressions of GlcNAc deacetylase (DAC1), 
hexokinase 1 (HXK1) and GlcNAc deaminase (NAG1) were all repressed in control hyphae as 
compared to the yeast form C. albicans; the expression of NGT1 remained unaltered (Figure 4). 
 
Figure 4 QRT-PCR analysis of the expression of GlcNAc metabolism genes. The relative gene 
expression of selected genes shows altered expression upon hyphae development as compared 
to yeast-like growth. First column (black bars) represents control hyphae; the second (open) 
and third (gray) columns stand for model hyphae and control hyphae + 10 mM of GlcNAc, 
respectively. Data are representative of 3 independent experiments and are presented as mean 
± SD. * 𝑝 < 0.05 
Lack of induction of these three genes may be due to the fact that these cells were 
cultured in a mammalian culture medium containing glucose. These results are in agreement 
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with a previous report, which showed that glucose did not significantly induce the expression 
of GlcNAc catabolism genes [14]. Furthermore, our results showed that the expression of all 
four genes (NGT1, DAC1, HXK1, and NAG1) genes involved in GlcNAc catabolism were all 
significantly upregulated in model hyphae and upon GlcNAc induction (Figure 4). 
Administration of 10 mM GlcNAc caused definite expression of the GlcNAc catabolic genes 
that is probably due to the high concentration of the substrate for catabolism (Figure 4). 
6.4.3. Virulence of HXK1 mutant Candida albicans is decreased 
We next sought to determine the importance of the GlcNAc metabolic pathway in the 
virulence of the fungus. Taking into account the genes involved in the GlcNAc catabolic 
pathway, many deletion mutants, such as ngt1Δ, hxk1Δ, nag1Δ, and dac1Δ, have a similar 
phenotype [49]; However nag1Δ and dac1Δ mutants could not grow on glucose if the medium 
contained GlcNAc [49]; hence we have chosen to use a hxk1Δ mutant strain in our subsequent 
experiments. We used an RTCA assay, which provides real-time, quantitative information 
about the number of the living, attached cells by measuring electrode impedance. Vaginal 
epithelial cells were treated with different numbers of yeast form C. albicans parental (DIC185) 
or mutant (hxk1Δ) strains, the impedance was measured for 24 hours and the data was converted 
to cell index (CI). Microscopic examination showed that both hxk1Δ and DIC185 strains 
behaved similarly in terms of germ tube formation and germ tube length in all inoculum 
concentrations during the experiment (data not shown). Our results showed, that the CI of non-
treated cells slightly increased, while cells treated with Triton X-100 rapidly detached from the 
plate surface because of massive cell lysis (Figure 5). When PK E6/E7 VECL cells were 
infected with low numbers (2000 and 5000) of C. albicans, the hxk1Δ mutant exhibited lower 
cytotoxicity as compared wild type (Figures 5a and 5b). When the number of infecting C. 
albicans cells was increased (10000 and 20000 cells), the hxk1Δ mutant no longer exhibited a 
reduced cytotoxic effect (Figures 5c and 5d). We also determined, that the cytotoxic effect 
exhibited by wild type C. albicans increased with the cell number used for infection (Figures 5 
and 6). Finally, when 2000 yeast cells were used for infection, the CI of vaginal epithelial cells 
infected with the hxk1Δ mutant was significantly higher at 16, 20, and 24 hours post infection 
as compared to the control DIC185 strain (Figures 6b, 6c, and 6d, resp.). At increasing C. 
albicans cell numbers used for infection, we only measured a significantly higher cell index of 
the hxk1Δ mutant at 16 hours post infection (5000 cells; Figure 6b). 
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Figure 5 Effect of C. albicans parental (DIC185) and hxk1Δ mutant (hxk1/hxk1) strains on the 
viability of PK E6/E7 vaginal epithelial cells. Cell index (CI) was measured using the RTCA 
method by xCELLigence System. CI was plotted as a function of time post infection. Different 
numbers of yeast form C. albicans were used as inoculum: (a) 2000 cells/well, 
(b) 5000 cells/well, (c) 10000 cells/well, and (d) 20000 cells/well. 
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Figure 6: Statistical analysis of the RTCA viability test. Cell indexes reflecting viability of PK 
E6/E7 vaginal epithelial cells infected with the same number of C. albicans parental (DIC185) 
and hxk1Δ mutant (hxk1/hxk1) strains were compared. Cell indexes were plotted as a function 
of inoculum size. Changes were considered statistically significant at p<0.05 (*); 
p<0.01 (**); and p<0.001 (***). 
6.4.4. GlcNAc is involved in the adherence of C. albicans to vaginal epithelial cells 
Numerous published data prove, that GlcNAc has a significant role in cell wall 
construction [76]. We hypothesized, that cell wall, and glycosylated cell wall proteins may have 
a key role in the adhesion to host cells and this could be an important factor in the decreased 
virulence of hxk1Δ strain. To determine if the GlcNAc pathway is involved in the attachment 
of C. albicans to the surface of vaginal epithelial cells, we carried out an adherence assay. 
Monolayers of PK E6/E7 vaginal epithelial cells were treated with 3 × 105 yeast form 
C. albicans parental (DIC185) and mutant (hxk1Δ) strains. After 90 min of contact, which is 
enough for C. albicans cells to form hyphae, non-adhered cells were washed away and the 
numbers of adherent C. albicans cells were counted. Our results showed, that significantly less 
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hxk1Δ mutant remained attached to the surface of the PK E6/E7 cells compared to the DIC185 
parental strain (Figure 7). This data indicates the importance of HXK1 gene and therefore the 
GlcNAc pathway in the adherence of C. albicans to vaginal epithelial cells. Noteworthy, it was 
published parallel with us, that GlcNAc could have a role in adhesion in other organisms, such 
as Staphylococcus aureus [77]. 
 
Figure 7 Adherence of the C. albicans parental strain DIC185 and hxk1Δ mutant to PK E6/E7 
vaginal epithelial cells. The 𝑦-axis represents the number of C. albicans cells, which remained 
adhered. The significance of differences between sets of data was determined by two-sample  
𝑡-test; *𝑝 < 0.05. 
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7. Results II 
7.1. Detection of DEGs with microarray meta-analysis 
In order to get reliable data about gene expression in lesional psoriatic skin samples, 
microarray meta-analysis was carried out. The study by Johnson-Huang et al. was already 
excluded after sample quality analysis with arrayQualityMetrics package, because at least two 
samples from one phenotype group are needed for MetaQC analysis and only one non-lesional 
sample remained after sample filtering. The overall quality of each study was assessed with 
MetaQC as described before [56]. The software calculated six quality control (QC) measures, 
then created principal component analysis biplot and standardized mean rank summary score 
to help in the identification of problematic studies. All five studies were defined as being non-
problematic based on quality values (Table 1). DEGs were identified by MetaDE [58]. 2307 
upregulated and 3056 downregulated genes were found in lesional skin samples compared to 
non-lesional ones. DEGs were used for network construction. The high number of DEGs (5363) 
in our study may be surprising, but it can be caused by the lower gene expression fold change 
cutoff (1.5 and -1.5 instead of 2 and -2) and by pre - filtering of samples, which can decrease 
variance and, thus, can increase the number of DEGs.  
Study GEO ID Platform/Chip NL L IQC EQC CQCg CQCp AQCg AQCp Rank 
Gudjonsson 
et al.[78] 
GSE13355 
GPL570/Affymetrix 
HU133 Plus 2.0 
54 53 4.18 4 307.65 307.65 95.2 292.19 2.17 
Yao et 
al.[79] 
GSE14905 
GPL570/Affymetrix 
HU133 Plus 2.0 
27 32 5.58 4 307.65 307.65 81.32 185.34 2.67 
Zaba et 
al.[80]  
GSE11903 
GPL571/Affymetrix 
HU133A 2.0 
15 12 7.34 3 307.65 307.65 79.24 260.95 2.75 
Suarez-
Farinas et 
al.[81] 
GSE30999 
GPL570/Affymetrix 
HU133 Plus 2.0 
79 80 0.86* 4 307.65 307.65 33 193.93 3.67 
Reischl et 
al.[82] 
GSE6710 
GPL96/Affymetrix 
HU133A 
12 12 2.7 4 307.65 271.23 40.3 118.68 3.92 
Johnson-
Huang et 
al.[83] 
GSE30768 
GPL571/Affymetrix 
HU133A 2.0 
1 4 Excluded by Array Quality Metrics package 
Table 1. Study information and QC measure summary. All studies were carried out on 
Affymetrix platforms. Asterisks indicate non-statistical significance of QC measures. More 
non-significant QC measures suggests potentially problematic studies. Study no 6 was already 
excluded by sample filtering with arrayQualityMetrics. Other studies had high quality and no 
outlier study was present. IQC: Internal Quality index, EQC: External Quality index, CQCg 
and CQCp: Consistency Quality Control indexes, AQCg and AQCp: Accuracy Quality Control 
indexes, NL: non-lesional sample count, L: lesional sample count 
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7.2. General Network analysis 
Undirected and directed PPI networks with DEG – coded proteins, directed PDI 
networks with DEG – coded TFs and regulated DEGs and merged directed networks containing 
both PPIs and PDIs were created. A TF-TF network consisting of DEG-coded TFs was also 
generated. The Cytoscape plugin NetworkAnalyzer calculated main network properties for both 
DEG-derived and control complete networks (Table 2).  
Network Nodes Edges Diameter Average shortest path 
PPI Undirected 1614 (9412) 5156 (55039) 14 (12) 4.79 (4.45) 
PPI Directed 464 (4040) 815 (13377) 14 (12) 5.26 (4.35) 
PDI 2840 (15839) 6398 (123210) 10 (7) 3.69 (3.029) 
Table 2 Results of general network analysis. DEG derived and control networks has similar 
attributes, but average shortest path length and network diameter is higher in DEG derived 
networks, which can be explained by lower connectivity (Figure 8). Values for control networks 
are in brackets. 
DEG – derived networks had higher diameter (i. e. the length of the longest shortest 
path in the network) and average shortest path length, than control full networks. This may be 
caused by the inverse correlation of node degree and fold change [84]. Nodes with lower fold 
change has higher degree. As genes with a fold change under cutoff are filtered out from DEG 
derived networks (between red lines on Figure 8), remaining nodes has smaller average degree, 
therefore connectivity of the network is lower resulting in higher diameter and average shortest 
path length value. 
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Figure 8 Degree-Fold Change relationship. Nodes with higher degree has lower fold change of 
gene expression in all network types. Genes between red lines have higher average degree and 
are filtered out from network analysis. Remaining nodes in DEG-derived networks have lower 
average degree and connectivity. 
7.3. Determination of hubs in DEG-derived networks 
Most important nodes of DEG-derived networks were determined using degree and/or 
stress centralities. Numerous psoriasis-associated protein-coding genes, which are already 
published, were found (Table 3). CCNA2, FYN and PIK3R1 proteins are yet unpublished in 
association with the disease and can be found in top rated hubs in undirected PPI network. PDI 
network contained DEG-coded TFs and regulated DEGs as nodes and directed edges pointing 
from the TFs to the regulated genes. TFs were ranked using the out-degree centrality. Androgen 
receptor (AR), TFDP1, MECOM and MEF2A were TFs above centrality cutoff, which are yet 
not associated with psoriasis.  
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PPI Undirected PPI Directed PDI 
Name 
Fold 
change 
Name 
Fold 
change 
Name 
Fold 
change 
IL8 67.31 IL8 67.31 TFDP1 4.61 
CCNB1 11.13 BIRC5 9.3 MECOM 1.7 
BIRC5 9.3 MMP1 7.45 AR -1.65 
STAT1 9.04 SOD2 7.2 NF1 -1.71 
CCNA2 8.74 IL1B 4.29 MEF2A -1.74 
CXCR4 5.11 STAT3 3.97     
IL1B 4.29 MMP9 3.66     
MAPK14 4.15 SOCS3 3.32     
STAT3 3.97 HMOX1 3.21     
MMP9 3.66 CCL2 2.9     
LCK 3.61 BAX 1.9     
AURKB 2.49 ICAM1 1.72     
MAPK1 1.82 CD69 1.72     
MYC 1.69 MYC 1.69     
NFKB1 1.64 CD86 1.68     
PCNA 1.62 CD28 1.64     
CDKN1A 1.58 NFKB1 1.64     
HDAC1 1.58 EGFR -1.61     
CYP1A1 -1.6 CTNNB1 -1.65     
EGFR -1.61 FN1 -1.75     
CREBBP -1.63 EDN1 -1.84     
CTNNB1 -1.65 SP1 -1.92     
FN1 -1.75 CTGF -2.04     
FYN -1.85 NFATC1 -2.19     
SP1 -1.92 IRS1 -2.28     
SMAD4 -1.95 INS-IGF2 -2.33     
INS-IGF2 -2.33 CCND1 -2.34     
CCND1 -2.34 FOS -2.36     
FOS -2.36 PPARG -2.56     
PPARG -2.56 BCL2 -2.63     
BCL2 -2.63 F3 -3.83     
PIK3R1 -2.96 LEP -6.27     
Table 3 Top rated nodes in DEG-derived networks. Central proteins with centrality value(s) 
above cutoff are listed. Fold change values between gene expression in lesional and non-
lesional samples are also shown. Proteins with bold characters are yet non-published in terms 
of psoriasis. 
7.4. Motif analysis in DEG-derived networks 
Motifs consisting of 3 or 4 nodes were analyzed in directed DEG-derived and control 
networks as well (Table 4). Analysis found motifs, which were enriched in directed DEG-
derived but were absent from control networks or vice versa. Some were already generally 
described in biological systems like convergent (no. 36), divergent (no. 6) and bifan (no. 204) 
motifs. 
 An interesting result of motif analysis is the enrichment of feedback loops (no. 98) in 
merged networks (PDI + PPI), but not in simple ones and the enrichment of motif no. 6356 in 
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DEG-derived merged network compared to control. Motif no. 6356 consist of a feedback loop 
and all nodes of the loop are controlled by another separated node. 
1 2
3
1 2
3
1 2
3
1 2
3
1 2
3 4
1 2
3 4
6
36
38
98
204
6356
 
Table 4 Summary of network motif analysis Numbers are p values of motif enrichment 
compared to 1000 random networks. Values with bold red characters are below 0.05 and thus 
significant. 
7.5. Controller sub-network construction 
Both lesional and non-lesional skin areas can be found on patients at the same time. We 
wanted to highlight nodes which may be important in the “all or none” switch in lesional skin 
areas and sustain this phenotype for a long time. To do this, we considered the following: It is 
reported, that positive feedback loops have fundamental role in maintaining autoimmune and 
autoinflammatory disease states [85]. It has also been argued that hubs can be found in much 
more positive feedback loops than negative ones [86]. This is published that in biological 
36 
 
systems, interlinked slow and fast positive feedback loops allow systems to convert graded 
inputs (like several environmental and genetic factors in a psoriatic individual) into decisive all 
or none outputs (like lesional skin phenotype) [85,87]. Enrichment of feedback loops (no. 98) 
and motif no. 6356 (consisting of a feedback loop with all nodes controlled by a separated one) 
also suggests central role of feedback in lesional skin. 
In order to find the most important positive feedback loops containing 2, 3 or 4 nodes, 
a merged PPI and PDI network was constructed from proteins with centralities above cutoff 
value. All feedback loops were identified with NetMatch. A positive feedback loop was selected 
if and only if expression of all nodes changed in the direction of sustaining or suppressing the 
activity of the loop and „activation” or „inhibition” properties of all edges were proven by 
publications. Expression of all nodes was downregulated in two loops having role in 
carbohydrate metabolism: the INS-IGF2-EDN1-LEP-INS-IGF2 and the LEP-PPARG-INS-
IGF2-LEP loop. The IL1B-NFKB1-CCL2-IL1B loop contained only upregulated nodes and 
has role in inflammation (Figure 10). The remaining loops contained inflammation and 
metabolism-related nodes as well. These may be key components in the metabolic-
inflammatory interplay in the pathomechanism of psoriasis. All positive feedback loops had 
common nodes, thus a merged network was generated containing interlinked positive feedback 
loops (Figure 10). Transcriptional changes of all nodes and influence of all edges supported the 
sustainment of lesional phenotype in this sub-network, which has been proven by Boolean 
analysis (Table 5). 
 Input state Relation Future state(*) 
NFATC* = FOS 0 0 0 
FOS* = EDN1 0 0 0 
EDN1* = NFATC1 and INS-IGF2 and LEP 0 0 and 0 and 0 0 
INS-IGF2* = PPARG and LEP 0 0 and 0 0 
LEP* = EDN1 and INS-IGF2 0 0 and 0 0 
PPARG* = INS-IGF2 and LEP and AR 0 0 and 0 and 0 0 
AR* = not (IL8 and NFKB1) 0 not (1 and 1) 0 
STAT3* = not AR 1 not 0 1 
IRF1* = STAT3 1 1 1 
IL8* = not PPARG; STAT3 and IRF1 and NFKB1 1 not 0; 1 and 1 and 1 1 
IL1B* = CCL2 1 1 1 
NFKB1* = not AR; IL1B 1 not 0; 1 1 
CCL2* = NFKB1 and IL1B 1 1 and 1 1 
Table 5. Boolean analysis of controller network Logical relations can be seen in the first and 
third column. Input and future state of network is stationary  
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Nodes with downregulated expression got value of 0 and nodes with upregulated 
expression got value of 1. Future state of nodes was set based on interactions (Table 5). The 
output Boolean values were the same as the input state suggesting constant future state of the 
system and, thus, the sustainment of lesional phenotype. 
 
Figure 10 Positive feedback loops and the merged controller sub-network in lesional psoriatic 
skin. Individual positive feedback loops with 2, 3 or 4 nodes are shown. Node color is blue if 
the gene expression is decreased and red if increased is lesional skin samples. Merged controller 
sub-network is shown on the top. Node color is proportional with fold change values. red line: 
gene regulatory interaction; blue line: protein-protein interaction; arrow-headed line: activation; 
bar-headed line: inhibition 
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7.6. Analysis of chemical-protein interaction networks 
Undirected and directed chemical-protein interaction networks were constructed using 
STITCH database, which contained interactions between proteins and chemical compounds 
(internal non-protein substances, drugs and environmental substances) [61]. Drugs or potential 
drugs were filtered out from chemicals and ranked by degree and stress centrality in case of 
undirected and out degree centrality in case of directed networks. Top ranked drugs were 
grouped into Anatomical Therapeutic Chemical (ATC) classes (Table 6) [88]. KEGG DRUG 
was used for classification [89]. Results showed a big overlap between undirected and directed 
network analysis. Best rated drugs were retinoic acid, cholecalciferol, costicosteroids, 
methotrexate, sirolimus and tacrolimus, which can be already found in psoriasis guidelines and 
large clinical trials have proved their effectiveness [90]. 
Psoriasis studies are available for numerous potential drugs with high centralities. 
“Blood glucose lowering drugs” are promising drug candidates. The biguanide metformin in 
this group is associated with reduced psoriasis risk in a population based case control study 
[91]. Many studies are available about “Thiazolidinedione” antidiabetic drugs. A recent meta-
analysis showed significant decrease in Psoriasis Area and Severity Index (PASI) scores 
compared to placebo in case of pioglitazone and non-significant improvement in PASI 50/70 
in case of rosiglitazone [92]. Troglitazone normalized histological features of psoriasis models 
and the lesional phenotype in a small clinical trial [93]. The “HMG CoA reductase inhibitor” 
drug simvastatin was effective in a pilot study, although atorvastatin in the same class showed 
only a non-significant improvement in a different study [94,95]. Salicylic acid has antifungal 
effects and it’s used as an adjuvant because of its keratolytic effect in the treatment of psoriasis 
[96]. The “Antineoplastic agent” methotrexate is a well-known medication for psoriasis. 
Several additional drugs in the same class were found in our analysis: studies are available for 
5-fluorouracil in the treatment of dystrophic psoriatic fingernails, but it showed only non-
significant improvement [97]; micellar paclitaxel significantly improved psoriasis in a 
prospective phase II study [98]. A study reported significant effectiveness of topical caffeine 
[99]. The “Calcium channel blocker” nifedipine is found to be an inductor of the disease in a 
case control study [100]. A study in 2005 reported significant PASI score reduction of 49.9% 
by topical theophylline ointment [101]. Mahonia aquafolium extract - containing berberine 
among others - is not classified into ATC classes, but three clinical trials already indicated 
improvement of psoriasis with the use of this substance [102]. Multiple studies prove efficacy 
of the terpenoid triptolide in the treatment of psoriasis [103]. A recent study investigated the 
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effect of rifampicin on psoriasis and reported a 50.03% mean PASI reduction [104]. A study 
about the treatment of psoriasis with curcumin was carried out, but reported only low response 
rate [105]. 
The efficacy of several drugs in results are supposed by in vitro experiments. The “Lipid 
modifying agent” clofibrate, but not bezafibrate reversed UVB-light-mediated expression of 
psoriasis – related inflammatory cytokines (IL6, IL8) [106]. Fluvastatin and pravastatin have 
the potential to inhibit Th17 cell chemotaxis, thus lowering immune cell infiltration of psoriatic 
skin [107]. Anti-proliferative effect of novel COX2 inhibitors on HaCaT keratinocytes was 
proven in an in vitro experiment and possible therapeutic use in psoriasis was supposed [108]. 
However, no such experiment was carried out with celecoxib which was the only COX2 
inhibitor in our results. N-acetyl-cysteine attenuated TNF alpha – induced cytokine production 
in primary human keratinocytes, which suggests its anti-psoriatic potential [109]. The 
“Thiazolidinedione” ciglitazone was never used as a drug, but inhibited keratinocyte 
proliferation in a dose dependent fashion [93]. Histone – deacetylase inhibitor trichostatin A 
blocked the conversion of regulatory T cells to IL17-expressing T cells suggesting its beneficial 
role in treating psoriasis [110]. Tse et al. supposed, that antiproliferative effect of arsenic 
compounds could have positive effects on psoriatic skin [111]. The phosphodiesterase inhibitor 
rolipram has the ability to block enterotoxin B-mediated induction of skin homing receptor on 
T lymphocytes and may have the potential to inhibit lymphocytic infiltration of lesional skin 
[112]. The natural polyphenolic compound rottlerin is a potent inhibitor of NFκB and may have 
disease modulating effects [113]. 
Case reports are available about psoriasis induction by clonidine, two “agents acting on 
the renin-angiotensin system” like captopril or losartan; the “protein kinase inhibitor” and 
“antineoplastic agent” imatinib; diclofenac, olanzapine, fluoxetine and chloroquine. Also case 
reports are available about the beneficial effects of ritonavir; “antineoplastic agents” like 
cytarabine, doxorubicin, and cysplatin; gefitinib, colchicine, lidocaine and nicotine [114-128]. 
In summary, studies are available for 34 drugs, experimental evidence is available for 
24 drugs, case reports suggest beneficial or disease-inductor effect of 21 drugs and we also 
found 98 unpublished drug candidates for the treatment of psoriasis (Table 6-7). 
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ATC Class Drugs 
STUDIES AVAILABLE 
Retinoids for topical use in acne retinoic acid 
Corticosteroids 
dexamethasone, hydrocortisone, corticosterone, 
prednisolone 
H2 receptor antagonists cimetidine 
Immunosupressants sirolimus, tacrolimus 
Antiinflammatory and antirheumatic drugs indomethacin 
Blood glucose lowering drugs excl. insulines metformin, troglitazone, rosiglitazone, pioglitazone 
Intestinal anti-inflammatory agents sulfasalazine 
Vitamins cholecalciferol, folic acid 
Antimycobacterials rifampicin 
Mineral supplements selenium 
Antifungals for topical use salicylic acid 
Antineoplastic agents 5-fluorouracil, methotrexate, paclitaxel, cycloheximide 
Cardiac stimulants excl. cardiac glycosides epinephrine-bitartrate, norepinephrine 
Lipid-modifying agents, plain simvastatin, atorvastatin-calcium 
Calcium channel blockers nifedipine 
Psychoanaleptics caffeine 
Thyroid therapy Liothyronine 
Drugs for obstructive airway diseases theophylline 
N/A berberine, curcumin, triptolide 
EXPERIMENTAL EVIDENCE 
Topical products for joint and muscular pain capsaicin 
Respiratory system N-acetyl-L-cysteine 
Antineoplastic agents Velcade, celecoxib 
Hormone antagonists and related agents tamoxifen 
Cardiac stimulants excl. cardiac glycosides isoproterenol 
Liver therapy glycyrrhizinic acid 
Antiinfectives and antiseptics, excl. 
combinations with corticosteroids 
arsenic 
Beta blocking agents propranolol 
Lipid-modifying agents, plain clofibrate, bezafibrate, fluvastatin, pravastatin 
Blood glucose lowering drugs excl. insulines ciglitazone 
N/A 
N-ethylmaleimide, baicalein, apigenin, SB 202190, 
monensin, rolipram, eflornithine, calphostin C, 
trichostatin A, rottlerin 
CASE REPORTS 
Antivirals for systemic use ritonavir 
Antiinflammatory and antirheumatic drugs diclofenac, ibuprofen, aspirin 
Antigout preparations colchicine 
Antiprotozoals chloroquine 
Ophtalmologicals atropine 
Antineoplastic agents 
cytarabine-hydrochloride, doxorubicin, cysplatin, 
imatinib, docetaxel, gefitinib 
Cardiac stimulants excl. cardiac glycosides phenylephrine 
Antiadrenergic agents, centrally acting clonidine 
Agents acting on the renin-angiotensin system captopril, losartan 
Anaesthetics lidocaine 
Psycholeptics olanzapine 
Psychoanaleptics fluoxetine 
Other nervous system drugs nicotine 
Table 6. Published Drugs 
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ATC Class Drug 
Retinoids for topical use in acne retinol 
Blood glucose lowering drugs excl. 
insulines 
glyburide 
Vitamin K and other hemostatics menadione 
Antineoplastic agents aldophosphamide, MLS003389283, etoposide, dasatinib, 
decitabine 
Sex hormones and modulators of the 
genital system 
(4-14c)pregn-4-ene-3,20-dione, mifepristone, testosterone-
propionate, androstanolone, diethylstilbestrol, raloxifene 
Hormone antagonists and related agents flutamide, fulvestrant 
Cardiac stimulants excl. cardiac glycosides bucladesine 
Cardiac glycosides G-Strophantin 
Drugs for obstructive airway diseases salbutamol 
Antiadrenergic agents, centrally acting reserpine 
Antiadrenergic agents, peripherally acting prazosin 
Lipid modifying agents, plain lovastatin, pitavastatin, fenofibrate 
Calcium channel blockers verapamil 
Diuretics furosemide, spironolactone 
Liver therapy silibinin 
Platelet aggregation inhibitors excl. 
heparin 
dipyridamole, cilostazol, amiloride-hydrochloride 
Agents acting on the renin-angiotensin 
system 
telmisartan, valsartan 
Anaesthetics ketamine, propofol, cocaine, isoflurane 
Analgesics morphine 
Psycholeptics haloperidol, clozapine, diazepam 
Psychoanaleptics desipramine, amitriptyline, metamphetamine 
Antiepileptics phenobarbital, valproic acid 
Antidotes naloxone 
Other nervous system drugs carbacholin 
N/A cytochalasin D, aminoguanidine, Neurogard, paraquat, Y27632, 
oxidopamine, nitroarginine, AC1LA4H9, SL327, emodin, 2,3,7,8-
tetrachlorodibenzo-dioxin, 3-(2-aminoethyl)-5-[(4-
ethoxyphenyl)methylidene]-1,3-thiazolidine-2,4-dione, 
CHEMBL248238, geldanamycin, anisomycin, 8-bromocyclic 
GMP, tempol, MK-801, 1-(5-isoquinolinesulfonyl)-2-
methylpiperazine, ionomycin, herbimycin, pyrrolidine 
dithiocarbamate, nordihydroguaiaretic acid, gamma-imino-ATP, 
forskolin, GMP-Pnp, roscovitine, flavopiridol, N-formyl-Met-Leu-
Phe, ns-398, sodium butyrate, AC1L1I8V, tyrphostin B42, kainic 
acid, pirinixic acid, IBMX, bisindolmaleimide I, proline-
dithiocarbamate, KBio2_002303, Zillal, thapsigargin, calcimycin, 
clenbuterol, indole-3-carbinol, 1,9-pyrazoloanthrone, herbimycin, 
kaempferol, daidzein, lithium-chloride, naringenin 
Table 7. Drug candidates unassociated with psoriasis 
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7.7. Effective drugs predominantly act on proteins of the controller sub-network 
The 32 effective drugs in the “Studies available” group were selected from STITCH 
data and target proteins were analyzed. All target proteins got an in-degree value reflecting the 
number of effective drugs acting on it. The group of proteins forming the controller sub-network 
was compared with the group of other targets. The controller sub-network protein group got 
significantly higher median value than the other one (10 vs. 1) with Mann-Whitney Rank Sum 
Test, which prove the importance of the controller sub-network in psoriatic lesions. (Figure 11) 
Noteworthy, that in-degree has power law distribution, thus T-test could not be used. 
 
Figure 11. Effect of anti-psoriatic drugs on controller network. A larger number of 
effective anti-psoriatic drugs act on controller nodes than on other proteins. Totally, the targets 
of 32 effective anti-psoriatic drugs were analyzed (median 10 vs. 1) *p<0.001 
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8. Discussion 
8.1. In vitro modelling vs. biopsy specimens 
8.1.1. Vulvovaginal Candidiasis 
We used in vitro modelling in our C. albicans study. We hypothesized, that although 
hyphal transition is an obligate step during pathogenesis, many other genes and processes are 
needed for virulence and, thus, hyphae growing in the presence of human cells may be markedly 
different from control hyphae, which is triggered only by physical environmental factors. One 
of the biggest challenge was to model VVC in vitro trustworthily. 
Secretions of the female genital tract keep the epithelial surface of the vagina moist. The 
lactic acid concentration of the vaginal fluid creates a pH of approximately 4.5 [129]. However, 
lactic acid concentration and pH similar to that of the vaginal fluid greatly inhibited cell division 
and germ tube formation of C. albicans in previous reports [130,131]. Thus, in our experimental 
model, C. albicans was cultured in CKM at pH 8.0. Culturing medium contained glucose at 
5.6 mM concentration. Glucose concentration of the vaginal fluid contains ~5.2 mM glucose as 
a final concentration [132]. Our RNA-Seq data showed strong upregulation of the 
gluconeogenesis, glyoxylate cycle, and fatty acid beta-oxidation pathways in both the control 
hyphae and hyphae developed in the presence of VECL (data not shown). This is in complete 
agreement with an earlier report, in which microarray analysis of phagocytosed C. albicans 
cells showed the upregulation of the glucose starvation related metabolic pathways, such as 
gluconeogenesis, glyoxylate cycle, and fatty acid beta-oxidation [133]. Noteworthy, 0.1% (w/v) 
glucose (5.6 mM) strongly induced hypha development of C. albicans on solid media [74]. 
Starvation to glucose may be one factor that drives the yeast to hyphae transition of C. albicans 
in our in vitro system. Additionally, we used the temperature of the human body (37 C) in our 
experiments, which also induces filamentation [11]. 
Although we tried to consider as many factors as possible during in vitro modelling, it 
had some limitations. First, hyphal growth of C. albicans is regulated by other microorganisms 
in the vaginal microbiome with yet unknown mechanisms. Additionally, we do not know the 
concentration of C. albicans cells relative to human cells in vivo, thus we used only empirical 
MOI. We used only one human cell type in our in vitro system, although there are numerous 
cell types in vivo. Though these drawbacks mentioned before, with the use of adequate controls 
(control hyphae and yeast), we were able to find important factors in the fungal-host interaction. 
44 
 
8.1.2. Psoriasis 
Several microarray studies were available for our in silico analysis of psoriasis. All of 
them assessed gene expression of punch biopsy specimens. Biopsy specimens are suitable for 
the investigation of complex diseases like psoriasis. Although the phenotype can be analyzed 
with its own complexity, there are also drawbacks available. First, in case of in vitro modelling, 
standardization is relatively easy, but in case of biopsy specimens it is cumbersome. We can 
select patients of the same age, gender, disease severity, treatment, but there can be numerous 
personal variations, which may have significant influence on gene expression. The goal of 
microarray meta-analysis is to avoid these variations and find uniform expression patterns 
among studies. Second, cellular-level gene expression analysis is difficult. There are in silico 
methods, which are able to determine cell-specific expression data from high throughput data 
of tissues, but the resolution of results is low and it is sometimes biased [134]. Single cell RNA 
sequencing is promising, but the dissection of different cell types from tissue specimens is 
problematic [135]. 
8.2. Filtering data and identification of important genes 
8.2.1. Vulvovaginal candidiasis 
As it could be seen from our two studies, filtering, normalization and the use of 
biostatistics is essential in high throughput gene expression studies. Although the price of RNA-
seq is getting lower, sometimes it is still too expensive to sequence the whole transcriptome 
separately of three or more biological replicates. As our goal was to identify proteins or 
processes consisting of several proteins potentially important for the virulence of C. albicans, 
we carried out RNA-seq for the pooled RNA of three biological replicates. The resultant data 
was capable for the identification of proteins or processes and the findings could be further 
explained and validated with other in vitro methods. As we had only pooled gene expression 
data for each experimental scenario, special statistical inference was needed for the detection 
of differentially expressed genes and most important results had to be validated with 
quantitative real time PCR using biological replicates. Numerous genes with a known role in 
pathogenesis have been detected in DEGs, but we focused on GlcNAc metabolism and 
investigated its potential role in adhesion. 
8.2.2. Psoriasis 
The purpose of a meta-analysis is to create general assumptions without the bias caused 
by geographical, ethnical, gender, study-design or age-related differences. The analysis process 
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for all microarray study were standardized and strict requirements were set for all of them. They 
had to be carried out on the same chip or chip family, and be suited to MIAME. We made the 
normalization and filtering process with the same methods for all studies. Quality assessment 
of all individual samples in a microarray study was carried out with ArrayQualityMetrics and 
all low-quality samples were excluded. Low-quality or outlier studies were further filtered with 
MetaQC. We wanted to construct whole networks from DEGs and make inference about 
network dynamics, thus, the selection of fold-change cutoff for DEGs was critical. Fold change 
cutoff selection is usually an empirical process. The same cutoff is chosen for all genes, 
although the expression range is affected by their function and network centralities [84]. We 
used the lower fold change cutoff of 1.5 instead of 2 to avoid the exclusion of potentially 
important proteins and genes. Noteworthy, lot of hubs in our analysis with highest centralities 
had lower, than 2 absolute fold change value, which can be caused by the negative correlation 
between degree and gene expression fold change values (Figure 8) [84]. The ideal method 
would be the selection of cutoff values for each gene individually considering their range of 
expression, which is already registered in other studies.  
We generated PPI networks based on the largest PPI database (STRING) available, 
which contains experimentally proven interactions as well as highly reliable ones based on 
prediction algorithms or data mining. PDI network was also generated using not only literally 
proven interactions but interactions predicted by high fidelity algorithms. The selection of 
nodes with highest centralities wasn’t straightforward too. Degree and stress node centralities 
represent power law distribution, thus, special statistical considerations were needed. The use 
of lower DEG fold-change cutoff and detailed analysis based on node centrality statistics made 
it possible to identify proteins yet not associated with the disease but may have remarkable role 
in its pathogenesis. 
8.3. Putting genes in context 
8.3.1. Vulvovaginal candidiasis 
Changes in the microenvironment massively induced many components of several 
different signal transduction pathways resulted in the morphological transition of C. albicans 
both in model and control conditions, but the GlcNAc transporter NGT1 was induced 
significantly exclusively in response to vaginal epithelial cells (Figures 3 and 4). We also found 
that the hxk1Δ mutant exhibits reduced cytotoxicity compared to the wild type strain of 
C. albicans, which may be caused by its decreased adherence to the surface of vaginal epithelial 
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cells (Figures 5 - 7). The human extracellular matrix contains a significant amount of GlcNAc 
[75]. In agreement with a recent review [75], GlcNAc released from the extracellular matrix of 
human cells during membrane remodeling might explain the induction of C. albicans GlcNAc 
catabolic genes, such as, NGT1, HXK1, NAG1, and DAC1 (Figure 4) by vaginal epithelial 
cells. 
Adherence to the surface of epithelial and endothelial cells and penetration of hyphae 
into these cells are important virulence factors contributing to the pathogenesis of C. albicans 
[19]. The GlcNAc biosynthesis plays a key role in chitin biosynthesis [75]. The inner layer of 
the cell wall of C. albicans consists of chitin (polymers of β-(1,3)-glucan, β-(1,6)-glucan, and 
GlcNAc). This scaffold binds glycosylphosphatidylinositol- (GPI-) anchor-dependent cell wall 
proteins, which play an important role in the adherence of C. albicans to the epithelial cells 
[11]. This suggest, that decreased adherence in hxk1Δ could be caused by decreased chitin 
synthesis. This theory is supported by a study, in which Nikkomycin Z, a chitin biosynthesis 
inhibitor caused reduced adherence of C. albicans to the surface of buccal epithelial cells [136]. 
8.3.2. Psoriasis 
Keratinocyte hyperproliferation and inhibition of apoptosis are well-known phenomena 
in psoriasis. Several proteins have been associated with these mechanisms like BCL2, BAX, 
NFATC1, PPARδ, EGF, mTOR, NF-κB etc.[137-140] Most of them could be found in the 
group of central proteins detected by DEG-derived network analysis. Unpublished DEG-coded 
proteins with potential role in hyperproliferation, like CCNA2, TFDP1 and MECOM, were also 
found (Table 3). CCNA2 encodes Cyclin A2, that controls S phase and G2/M transition. A 
recent study reported that CCNA2 protein has role in cytoskeletal rearrangements and cell 
migration as well [141]. Not only cell cycle progression is abnormal in lesional skin, but actin 
cytoskeleton organization as well [142]. Thus, Cyclin A2 may take part in hyperproliferation 
and in aberrant actin cytoskeleton organization in psoriatic skin keratinocytes. TFDP1 encodes 
DP1 protein, which is a dimerization partner of the E2F transcription factor. The E2F/DP1 
heterodimers regulate cell cycle via DNA replication control and apoptosis. DP1 has E2F-
independent function as well: DP1 can stabilize Wnt-on and Wnt-off states in Wnt/β-catenin 
signaling and determine differential cell fates [143]. 
Psoriasis is an immune-mediated disease. Some proteins, which are published as 
important factors in pathogenesis, were absent from DEGs in our microarray-meta analysis. For 
example TNF alpha was not identified as a hub, although it is an important target in psoriasis 
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therapy. This could be explained by the finding that increased TNF alpha in psoriatic plaques 
are caused mainly by post-transcriptional mechanisms [144]. Many proteins published in 
association with the immunopathogenesis of psoriasis were highly ranked hubs in PPI 
networks: IL1, IL8, TGFB1, SP1, STAT1, STAT3, NFKB1, IRF1 etc.[139,145-151] The 
downregulation of the src kinase FYN seems to be a counteracting compensatory mechanism 
as this protein is important in IFN gamma action, in TNF alpha induced COX2 expression and 
in adipose tissue - mediated inflammation leading to insulin resistance. These processes are 
important in the pathomechanism of psoriasis [152-154]. This data is in agreement with our 
chemical-protein interaction network analysis, which suggests, that the FYN inhibitor 
KBio2_002303 may have beneficial effects in the treatment of psoriasis. An important node in 
controller sub-network is IL8. Although its role in psoriasis pathogenesis is reported, no trial 
has been done with IL8 inhibitors [155]. This is true for CCL2 and IRF1 as well. Our study 
confirms their basic role in the sustainment of lesional phenotype as both can be found in highly 
ranked hubs. CCL2 is also essential in the controller sub – network by activating two positive 
feedback loops related to inflammation. 
Comorbidity of psoriasis and metabolic syndrome is a well-known phenomenon. There 
is a complicated interaction between the two diseases mediated by inflammatory cytokines 
among other factors [156]. Numerous DEG-coded proteins associated with both diseases could 
be found in central proteins like PPARG, INS-IGF2, LEP etc. (Table 3) [157-159] Others, like 
PIK3R1, AR and MEF2A may have role in the development of metabolic syndrome in psoriatic 
patients. PI3KR1 is important in the development of insulin resistance, it propagates 
inflammatory response in obese mice and may be an important link between the obesity-
inflammation interplay in psoriasis [160]. AR has important effect on insulin signaling and thus 
insulin resistance. It is published that AR knockout mice exhibit insulin resistance [161]. To 
our knowledge, AR has not yet been associated with psoriasis. However it was found in 1981, 
that lower serum testosterone level therefore decreased AR activation can be detected in 
psoriatic patients [162]. AR and PPARG connect inflammation- and metabolism-related hubs 
in controller network. MEF2A is important for GLUT4 expression on insulin-responsive cells. 
Expression of MEF2A is downregulated in lesional skin samples which suggests another 
possible mechanism for insulin resistance in psoriasis. 
The real purpose of systems biology is to construct models from high throughput data. 
High precision data is needed for reliability. We used data of gene expression in our psoriasis 
study. We didn’t measure protein abundance and didn’t assess allosteric modulation of proteins 
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or generation of protein complexes. Additionally we didn’t have expression data for different 
time points. Thus, an accurate model with differential equations could not be constructed. 
However, we were able to detect a sub-network with the use of network motif analysis, which 
could potentially induce and maintain the lesional phenotype of the disease. 
8.4. Therapeutic aspects 
Chemical – protein interaction networks were created using STITCH database and we 
managed to predict disease – modifying drugs. Many drugs, which are already widely used in 
the treatment of psoriasis could be found as highly ranked nodes in chemical-protein interaction 
networks such as methotrexate, retinoic acid, corticosteroids, sirolimus and tacrolimus (Table 
6). According to STITCH data, all of them act on at least one of the hubs in the controller sub-
network. Members of highly ranked ATC classes also target proteins in the controller sub-
network. Blood glucose-lowering drugs act through PPARG and INS-IGF2 activation and 
fibrate and HMG-CoA inhibitors may improve psoriasis through the modulation of these 
proteins as well [92]. Cardiac stimulants such as adrenergic agents also have high impact on 
PPI and PDI network mainly by modulating hubs in the controller sub-network. Members of 
the “Sex hormones and modulators of the genital system” ATC class act on AR.  
The “antineoplastic drug” methotrexate mainly acts through the accumulation of 
adenosine, but the other antineoplastic agents may act in a different manner like the inhibition 
of keratinocyte hyperproliferation [163]. Studies or case reports already suggest efficacy of 
some antineoplastic drugs, but several new possible agents were found in our analysis 
[98,164,165]. Mental stress is known to trigger psoriasis and connection between the 
neuroendocrine system and skin immune system has already been reported [26,166]. Thus, this 
is not surprising, that numerous drugs acting on the CNS are enriched in results. A lot of other 
drugs, which are either classified in ATC classes or just drug candidates, are found. For example 
kainic acid, cocaine, the HDAC inhibitor sodium butyrate, the PKC inhibitor 
bisindolylmaleimide I etc. (Table 7) 
Our results suggested, that the fusion of different intracellular networks with chemical-
protein interaction networks can be an effective method for the detection of potentially effective 
drugs in the treatment of psoriasis. Our intracellular networks were constructed with the use of 
DEGs, which characterize the lesional phenotype in itself. The integration of drug-protein 
interaction data in this system seemed to be a powerful tool for drug discovery of psoriasis. The 
rather, that other research groups have proven the efficacy of some predicted drugs since the 
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publication of our results. For example, the role of aryl hydrocarbon receptor in chronic 
inflammatory skin diseases was reported recently and drugs targeting this receptor were found 
in our analysis (Table 7) [167]. 
8.5. The place of systems biology in dermatological research 
Large amount of “omics” data was generated in the past decades in parallel with the 
improvement of screening technologies. As our VVC study showed, virulence factors can be 
identified with the use of experimental models and carrying out transcriptome analysis. New 
and important findings can be acquired by the analysis of published data too. We were able not 
only to identify new proteins in the pathogenesis of psoriasis, but to find new therapeutic 
options for the disease. 
We have demonstrated two examples, how large scale data of multifactorial 
dermatological diseases can be used. The use of large datasets, analyzing them with the tools 
of bioinformatics and biostatistics is inevitable in this modern era of biomedical research. We 
have become able to understand complex processes, construct models of diseases and treat them 
more effectively.  
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